Li Mou Zheng
Founder chez AMOY DIAGNOSTICS CO., LTD.
Fortune : 265 M $ au 31/03/2024
Profil
Li Mou Zheng is the founder of Amoy Diagnostics Co., Ltd., which was founded in 2008.
He currently holds the position of Chairman at Amoy Diagnostics Co., Ltd.
Additionally, Dr. Zheng is currently the Chairman at SinoPath Medical Investment (Beijing) Co., Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/09/2023 | 87 701 616 ( 22,06% ) | 265 M $ | 31/03/2024 |
Postes actifs de Li Mou Zheng
| Sociétés | Poste | Début |
|---|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Founder | 21/02/2008 |
SinoPath Medical Investment (Beijing) Co., Ltd.
 SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Chairman | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
SinoPath Medical Investment (Beijing) Co., Ltd.
SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Health Services |
